Paper Details

  1. Home
  2. Paper Details

Acute and long-term safety and tolerability of risperidone in children with autism.

Author: AmanMichael G, ArnoldL Eugene, ChuangShirley, DaviesMark, GhumanJaswinder K, GonzalezNilda M, KoenigKathleen, LindsayRonald L, MartinAndres, McCrackenJames T, McDougleChristopher J, McGoughJames, NashPatricia L, PoseyDavid J, RitzLouise, ScahillLawrence, ShahBhavik, SwiezyNaomi B, TierneyElaine, VitielloBenedetto

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the safety and tolerability of risperidone in children and adolescents with autism. The most common side effects were somnolence and weight gain. These side effects were generally mild to moderate and did not interfere with therapeutic changes.
Paper Details　
Original Abstract of the Article :
Treatment-emergent adverse events (AEs) were monitored during an 8-week, double-blind, placebo-controlled trial of risperidone (0.5-3.5 mg/day) in 101 children and adolescents with a lifetime diagnosis of autistic disorder. In addition, 37 placebo nonresponders received open-label risperidone for an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/cap.2005.15.869

データ提供：米国国立医学図書館（NLM）

Risperidone: Navigating the Landscape of Autism Treatment

Autism spectrum disorder (ASD) presents unique challenges for both individuals and their families. This study focused on the safety and tolerability of risperidone, a medication often used to manage certain behavioral symptoms associated with ASD. The researchers conducted a double-blind, placebo-controlled trial involving 101 children and adolescents with ASD. They found that risperidone was generally safe and well-tolerated, with the most common side effects being drowsiness and weight gain. This research is like a meticulous explorer charting the uncharted territory of autism treatment.

Risperidone: A Careful Approach to Managing ASD Symptoms

This study serves as a valuable guide for clinicians and families navigating the landscape of ASD treatment. The researchers found that risperidone can be a helpful tool for managing certain behavioral symptoms associated with ASD. However, they also emphasized the importance of carefully monitoring potential side effects, such as drowsiness and weight gain. This research is like a map guiding you through the complex terrain of ASD treatment.

Risperidone: A Balanced Approach to ASD Treatment

This study highlights the importance of a balanced approach to ASD treatment. Risperidone can be a helpful tool for managing certain behavioral symptoms, but it's crucial to weigh its potential benefits against its potential side effects. This research is like a well-placed oasis in the desert of ASD treatment, offering a refreshing perspective on managing this complex condition.

Dr.Camel's Conclusion

This study, like a camel navigating a vast desert, sheds light on the safety and effectiveness of risperidone in treating autism. The researchers' findings provide valuable insights into the potential benefits and risks of this medication. While risperidone can be helpful for managing certain behavioral symptoms, it's essential to carefully monitor potential side effects and weigh the benefits against the risks. This research serves as a valuable guide for clinicians and families in making informed decisions about ASD treatment.

Date :
  1. Date Completed 2006-04-03
  2. Date Revised 2016-11-22
Further Info :

Pubmed ID

16379507

DOI: Digital Object Identifier

10.1089/cap.2005.15.869

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.